These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 17071475)

  • 21. Platelet response during the second cycle of decitabine treatment predicts response and survival for myelodysplastic syndrome patients.
    Jung HA; Maeng CH; Kim M; Kim S; Jung CW; Jang JH
    Oncotarget; 2015 Jun; 6(18):16653-62. PubMed ID: 25938546
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Danazol for the treatment of thrombocytopenia in patients with myelodysplastic syndrome.
    Chan G; DiVenuti G; Miller K
    Am J Hematol; 2002 Nov; 71(3):166-71. PubMed ID: 12410570
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Platelet apoptosis and agonist-mediated activation in myelodysplastic syndromes.
    Martín M; de Paz R; Jiménez-Yuste V; Fernández Bello I; García Arias Salgado E; Alvarez MT; Butta NV
    Thromb Haemost; 2013 May; 109(5):909-19. PubMed ID: 23407717
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin.
    Isaacs C; Robert NJ; Bailey FA; Schuster MW; Overmoyer B; Graham M; Cai B; Beach KJ; Loewy JW; Kaye JA
    J Clin Oncol; 1997 Nov; 15(11):3368-77. PubMed ID: 9363868
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thrombocytopenia in MDS: epidemiology, mechanisms, clinical consequences and novel therapeutic strategies.
    Li W; Morrone K; Kambhampati S; Will B; Steidl U; Verma A
    Leukemia; 2016 Mar; 30(3):536-44. PubMed ID: 26500138
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study.
    Vey N; Bosly A; Guerci A; Feremans W; Dombret H; Dreyfus F; Bowen D; Burnett A; Dennis M; Ribrag V; Casadevall N; Legros L; Fenaux P
    J Clin Oncol; 2006 Jun; 24(16):2465-71. PubMed ID: 16651646
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine.
    Greenberg PL; Garcia-Manero G; Moore M; Damon L; Roboz G; Hu K; Yang AS; Franklin J
    Leuk Lymphoma; 2013 Feb; 54(2):321-8. PubMed ID: 22906162
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Successful use of rituximab in platelet transfusion refractoriness in a multi-transfused patient with myelodysplastic syndrome.
    Yu QH; Shen YP; Ye BD; Zhou YH
    Platelets; 2015; 26(2):195-6. PubMed ID: 23634876
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes.
    Schiller GJ; Slack J; Hainsworth JD; Mason J; Saleh M; Rizzieri D; Douer D; List AF
    J Clin Oncol; 2006 Jun; 24(16):2456-64. PubMed ID: 16651647
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical study of rhIL-11 for prevention and treatment of chemotherapy-induced thrombocytopenia].
    Sun XF; Guan ZZ; Huang H; Zhou QH; Yi C; Zhang LJ; Zhu J; Li R; Zhou J; Zhang M; Guo Y
    Ai Zheng; 2002 Aug; 21(8):892-5. PubMed ID: 12478901
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dose reductions and delays: limitations of myelosuppressive chemotherapy.
    Cairo MS
    Oncology (Williston Park); 2000 Sep; 14(9 Suppl 8):21-31. PubMed ID: 11033835
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Subcutaneous granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome: toxicity, pharmacokinetics, and hematological effects.
    Thompson JA; Lee DJ; Kidd P; Rubin E; Kaufmann J; Bonnem EM; Fefer A
    J Clin Oncol; 1989 May; 7(5):629-37. PubMed ID: 2651578
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thrombopoietic activity of recombinant human interleukin 11 (rHuIL-11) in normal and myelosuppressed nonhuman primates.
    Schlerman FJ; Bree AG; Kaviani MD; Nagle SL; Donnelly LH; Mason LE; Schaub RG; Grupp SA; Goldman SJ
    Stem Cells; 1996 Sep; 14(5):517-32. PubMed ID: 8888493
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacoeconomic analysis of oprelvekin (recombinant human interleukin-11) for secondary prophylaxis of thrombocytopenia in solid tumor patients receiving chemotherapy.
    Cantor SB; Elting LS; Hudson DV; Rubenstein EB
    Cancer; 2003 Jun; 97(12):3099-106. PubMed ID: 12784347
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recombinant human interleukin-11 (IL-11) is a protective factor in severe sepsis with thrombocytopenia: A case-control study.
    Wan B; Zhang H; Fu H; Chen Y; Yang L; Yin J; Wan Y; Shi Y
    Cytokine; 2015 Dec; 76(2):138-143. PubMed ID: 26276375
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase 1/2 study of rigosertib in patients with myelodysplastic syndromes (MDS) and MDS progressed to acute myeloid leukemia.
    Navada SC; Fruchtman SM; Odchimar-Reissig R; Demakos EP; Petrone ME; Zbyszewski PS; Holland JF; Silverman LR
    Leuk Res; 2018 Jan; 64():10-16. PubMed ID: 29144985
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomised cross-over study.
    Vadhan-Raj S; Kavanagh JJ; Freedman RS; Folloder J; Currie LM; Bueso-Ramos C; Verschraegen CF; Narvios AB; Connor J; Hoots WK; Broemeling LD; Lichtiger B
    Lancet; 2002 Jun; 359(9324):2145-52. PubMed ID: 12090979
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of rhIL-11 on normal dogs and after sublethal radiation.
    Nash RA; Seidel K; Storb R; Slichter S; Schuening FG; Appelbaum FR; Becker AB; Bolles L; Deeg HJ; Graham T
    Exp Hematol; 1995 May; 23(5):389-96. PubMed ID: 7720811
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thrombopoiesis-stimulating agents and myelodysplastic syndromes.
    Brierley CK; Steensma DP
    Br J Haematol; 2015 May; 169(3):309-23. PubMed ID: 25659186
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Phase II clinical trial on China manufactured recombinant human interleukin-11 derivative in the prevention and treatment of chemotherapy-induced thrombocytopenia].
    Wang XY; Feng FY; Song ST; Wang HQ; Zhang MH; Liu J; Liu XY; Xu LG; Zhang Y
    Zhonghua Zhong Liu Za Zhi; 2005 Jun; 27(6):373-6. PubMed ID: 16117903
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.